Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant

Stopped early · Phase 2

Conditions studied: Hodgkin's Lymphoma, Multiple Myeloma, Non-Hodgkin's Lymphoma

In brief

Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.

Key facts

Study ID

NCT01699581

Run by

Greg Monohan

People needed

35

Starts

2012-09-01

Expected to finish

2015-10-01

Last updated by the study team

2016-10-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2
• Any prior diet or supplement will be allowed.
• Age >18 years.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nestle Impact including fish oil.

Where it is running

• University of Kentucky, Markey Cancer Center — Lexington, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.